Kanger signs MoU with Sabah Govt to procure China’s Sinopharm Covid-19 vaccines

Kanger signs MoU with Sabah Govt to procure China’s Sinopharm Covid-19 vaccines
-A +A

KUALA LUMPUR (May 27): Kanger International Bhd has inked a Memorandum of Understanding (MoU) with the Sabah Government to procure and import China’s Sinopharm Covid-19 vaccines.

Under the MoU, Kanger will source the Sinopharm vaccines from abroad to be supplied to the Sabah Government, while the State Government appoints Kanger as the exclusive distributor of the vaccines in the State, subject to the approval of the Federal regulatory authorities.

Commenting on the three-year deal, Kanger executive director Steven Kuah Choon Ching said the group believes that collaboration between the public and private sectors can help to accelerate the vaccine roll out in the country.

“With Sabah being the second State in Malaysia with the highest number of cases with over 60,000 to date, it is our aim that this partnership will strengthen the government of Sabah’s efforts in combating the Covid-19 outbreak in Sabah.

“We will ensure that we obtain the required approvals from relevant authorities before we commence distribution of the Sinopharm vaccines.

“Once approvals are obtained, the people of Sabah will be one of the early recipients of the Sinopharm vaccines,” Kuah said.

The Sinopharm Covid-19 vaccine is in the process of being approved in Malaysia, including by the National Pharmaceutical Regulatory Agency (NPRA).

Kuah said Kanger is proud to play a part and support Sabah in its fight against the pandemic.

"We hope that this will be the first of more fruitful ventures with the government of Sabah,” he said.

He added that the group will be exploring opportunities to extend the distribution of the Sinopharm  vaccines to all other States in Malaysia.

The Sinopharm Covid-19 vaccine has been approved by the World Health Organization for emergency use and is currently being administered in 42 countries, including China, the United Arab Emirates and Morocco, with more than 200 million doses supplied globally so far.

It is proven to have an efficacy of 79% for people aged 18 years old and above.

Shares of Kanger ended unchanged at 10 sen today, valuing the group at RM274.99 million.

S Kanagaraju